恶性疟原虫红细胞结合抗原175肽段4的人源抗体分析
Analysis of human antibodies to erythrocyte binding antigen 175 peptide 4 of Plasmodium falciparum.
作者信息
Touré Fousseyni S, Deloron Philippe, Migot-Nabias Florence
机构信息
Centre International de Recherches, Médicales de Franceville, BP 769 Franceville, Gabon.
出版信息
Clin Med Res. 2006 Mar;4(1):1-6. doi: 10.3121/cmr.4.1.1.
BACKGROUND
The IgG1 and IgG3 antibodies are considered cytophilic and protective against Plasmodium falciparum, whereas IgG2 and IgG4 are thought to block protective mechanisms.
OBJECTIVES
The main objective was to measure antibodies directed against erythrocyte binding antigen-175 (EBA-175) peptide 4 and analyze the relationship between such antibodies and clinical malaria attack.
METHODS
Using an enzyme-linked immunosorbent assay, a retrospective analysis of naturally acquired antibodies to synthetic peptide from EBA-175 peptide 4 has been carried out in 158 school children from the village of Dienga in Gabon.
RESULTS
The overall prevalence rates of antibodies to EBA-175 peptide 4 were 85.2%, 66.8%, 52.6%, 71.6% and 64.0% for total IgG, IgG1, IgG2, IgG3 and IgG4, respectively. Protection from clinical malaria, determined after a prospective 1-year study, was associated with the levels of IgG and IgG1 antibodies that increased with age.
CONCLUSION
Together, these data suggest that age/exposure-related acquisition of anti-EBA-175 antibodies may contribute to the development of clinically protective immunity and could be taken into account in malaria control strategies when they are confirmed.
背景
IgG1和IgG3抗体被认为具有亲细胞性且对恶性疟原虫具有保护作用，而IgG2和IgG4则被认为会阻断保护机制。
目的
主要目的是检测针对红细胞结合抗原175（EBA-175）肽段4的抗体，并分析此类抗体与临床疟疾发作之间的关系。
方法
采用酶联免疫吸附测定法，对加蓬迪恩加村的158名学童中针对EBA-175肽段4合成肽的自然获得性抗体进行了回顾性分析。
结果
针对EBA-175肽段4的抗体总患病率分别为：总IgG为85.2%、IgG1为66.8%、IgG2为52.6%、IgG3为71.6%、IgG4为64.0%。经过为期1年的前瞻性研究确定，预防临床疟疾与IgG和IgG1抗体水平相关，且这些抗体水平随年龄增长而升高。
结论
总体而言，这些数据表明，与年龄/暴露相关的抗EBA-175抗体的获得可能有助于临床保护性免疫的发展，一旦得到证实，在疟疾控制策略中可予以考虑。
Zotero 插件